Zura Bio Financial Results
Zura Bio reported third quarter 2026 financial results, highlighting a cash position of $187.7 million which is expected to fund operations through 2028. The company remains on track for topline Phase 2 data readouts for tibulizumab in hidradenitis suppurativa (Q4 2026) and systemic sclerosis (H1 2027).
“Our team continues to execute efficiently on our development plan for tibulizumab, and we are excited as we enter this data-rich period for the company. We are on track to report topline results from our TibuSHIELD study in HS later this quarter, followed by topline results from our TibuSURE study in SSc in the first half of 2027.”
Sandeep Kulkarni, M.D., co-founder and Chief Executive Officer
“We continue to believe deeply in tibulizumab’s potential to address complex immune biology and unmet needs across indications, including in PMR, where we will be starting the NEXUS-PMR study by end of year. With cash runway sufficient to deliver results from all three studies, Zura is in a great position to deliver on tibulizumab’s unique potential.”
Sandeep Kulkarni, M.D., co-founder and Chief Executive Officer